The level of C-erbB-2 in patients with esophageal and gastric cancers

Year 2021, Volume: 3 Issue: 3, 208 - 213, 14.07.2021

Serkan Cerrah , Salim Başol Tekin

https://doi.org/10.38053/acmj.915839

Abstract

Aim: In this study, we aimed to reveal the prevalence of c-erbB-2 expression in patients with gastric and esophageal cancers in the Eastern Anatolia Region and their relationships with pathologic parameters.
Material and Method: A total of 50 patients, 25 esophageal cancer and 25 gastric cancer patients, who were diagnosed and operated in three clinics at Atatürk University, School of Medicine (Internal Medicine, General Surgery, and Thoracic Surgery) between 2000-2007, were retrospectively included in the study. The parameters belonging to these cases, such as histologic type, differentiation degree, tumor invasion depth, and lymph node metastasis, were extracted from the pathology reports. We obtained the preparations from pathology laboratory archives and reexamined them. Those suitable for immunohistochemical stain were selected from the paraffin block archive and undergone to immunohistochemical process.
Results: We detected c-erbB-2 positivity in 6 (24%) of 25 patients with esophageal cancer and 7 (%28) of 25 patients with gastric cancer. The relationships between c-erbB-2 expression scores and the selected parameters were evaluated using the Chi-square test. Ultimately, we found no significant relationships between c-erbB-2 positivity and differentiation degree (p=0.447), tumor invasion depth (p=0.067), and lymph node metastasis (p=0.461). Despite no statistical relationships, esophageal cancer cases with positive c-erbB-2 displayed noticeable features, such as lymph node involvement and well-differentiated tumors. In the cases with gastric cancer, there were no statistical relationships between c-erbB-2 positivity and the WHO classification (p=0.748), the Lauren classification (p=0.373), lymph node metastasis (p=0.629), tumor invasion depth (p=0.262), and differentiation degree (p=0.083). However, by the WHO classification, lymph node involvement and tubularity were noticeable features of all cases with c-erbB-2 positivity.
Conclusion: Larger and further studies are needed to more clearly observe the effect of C-erbB-2 expression on clinicopathological outcomes in gastric and esophageal cancers.

Keywords

c-erbB-2, gastric cancer, esophageal cancer

References

• Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma I: a critical review of surgery. Br J Surg 1980; 67: 381-90.
• King RM, Pairolero PC, Trastek VF. Ivor Lewis esophagastrectomy for carcinoma of the esophagus: early and late functional results. Ann Thorac Surg 1987; 44: 119-22.
• Klumpp T, Macdonald JS, Esophageal cancer: epidemiology and pathology. In Ahlgreen J, Macdonald J. (ed)s. Gastrointestinal Oncology. Philadelphia: JB Lippincott Company 1992; 71-80.
• Kanserle Savaş Politikası ve Kanser Verileri (1995-1999), T.C Sağlık Bakanlığı Kanserle Savaş Dairesi Başkanlığı, Ankara 2002: 12-6.
• Peters JH, De Meester TR, Essophagus and dipragmatic hernia. Ed: Schwartz Sl, Shires TG, Spencer FC, et al. Principles of Surgery. 7th ed. McGraw-Hill, 1999:1081-180.
• Becker KF, Keller G, Hoefler. The use of molecular biology in diagnosis and prognosis of gastric cancer. Surg Oncol 2000; 9: 5-11.
• Truszkowski JA, Summers RW. Colorectal Neoplasms. Postgraduate Med 1996; 98: 20-5.
• Başaran N.Tıbbi Genetik. Eskişehir, Bilim Teknik Yayınevi 1196: 357-68.
• Sherman CD. Klinik Onkoloji. Türk Kanser Araştırma ve Savaş Kurumu yayınları, Ankara 1190: 3-9.
• AOO Chan, SK Lam, KM Chu, et al. Soluble Ecadherin is a valid prognostic marker in gastric carcinoma. Gut 2001; 48: 808-11.
• David N L, Klaus JL. Malignant: adenocarcinoma, stomach. In: Weidner N, Cote RJ, Suster S, Weiss LM, (ed)s. Modern Surgical Pathology Fist ed. Saunders; 2003: 672-80.
• Yonemura Y, Ninomiya I, Yamaguchi A. Evalution of immünreactivity for c-erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991; 51: 1034-8.
• Flejou JF, Paraf F, Muzeau F, et al. Expression of c-erbB-2 oncogene product in Barrett’s adenocarcinoma: Pathological and prognostic correlations. J Clin Pathol 1994; 47: 23-6.
• Ueda M. New prognostic factors in patients with esophageal squamaus carcinoma. Gan To Kagaku Ryoho 1992; 19: 20-5.
• Ross JS, Sheean C, Hayner Buchan AM, et al. HER-2/neu gene amplication status in prostate cancer by flourescence insutu hybridization. Hum Pathol 1997; 28: 827-33.
• Kern JA, Schwartz DA, Nordberg JE. P185/neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990; 50: 5184-9.
• Ross JS, Fletcher JA. C-erbB-2 gene and protein in breast cancer. Am J Clin Pathol 1999; 112: 53-7.
• Yarden Y. Biology of HER2 and it’s importance in breast cancer. Oncology 2001; 61: 1-13.
• Yoshida K, Kuniyasu H, Yasui W, et al. Expression of growth factors and their receptors in human esophageal carcinomas: Regulation of expression by epidermal growth factor and transforming growth factor alpha. J Cancer Res Clin Oncol 1993; 119: 401–7.
• Dreilich M, Wanders A, Brattstrom D. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus 2006;19: 224–31.
• Suo Z, Su W, Holm R. Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinomas. Anticancer Res 1995; 15: 2797–8.
• Lam KY, Tin L, Ma L. C-erbB-2 ptotein expression in a esophageal squamous epithelium from esophageal squamous cell carcinoma with special reference to histological grade of carcinoma and pre-invasive lesions. Eur J Surg Oncol 1998; 24: 431-5.
• Sauter ER, Keller SM, Erner S. HER-2/neu: A differentiation marker in adenocarcinoma of the esophagus. Cancer Lett 1993; 75: 41–4.
• Dursun A, Poyraz A, Çelik B, Akyol G. Expression of c-erbB-2 Oncoprotein in gastric carcinoma: correlation with histopathologic charesteristic s and analysis of Ki-67. Pathol Oncol Res 1999; 5: 104-6.
• Tanner M, Hollmen M, Junntilla T, et al. Amplication of HER-2 in gastric carcinoma: assosiacion with Topoisomerase 2 gene amplification, intestinal type, poor prognosis and sensitivity to transtuzumab. Ann Onc 2005; 16: 273-8.
• Yıldırım S, Dandin O, Durmuş M, et al. C-erb-B2 (Her2/neu) expression rate and its association with clinicopathologic parameters in gastric cancer. Int J Hematol Oncol 2012: 3: 156-62.